Nanjing Vazyme Biotech Co., Ltd. (688105.SS)

CNY 23.21

(-1.9%)

Market Cap (In CNY)

9.21 Billion

Revenue (In CNY)

1.28 Billion

Net Income (In CNY)

-70.95 Million

Avg. Volume

1.11 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
16.85-32.99
PE
-
EPS
-
Beta Value
1.011
ISIN
CNE100004ZK3
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Lin Cao
Employee Count
-
Website
https://www.vazyme.com
Ipo Date
2021-11-15
Details
Nanjing Vazyme Biotech Co., Ltd., a biotechnology company, engages in the research, development, and production of enzymes, antigens, antibodies, and polymer organic materials. The company offers scientific research reagents, such as PCR clone point mutation, nucleic acid extraction, reverse transcription, qPCR, cell/protein, gene editing series, and instant granules; high-throughput sequencing library construction reagents, including DNA and RNA library, single cell epigenetic, magnetic, quantitative series, and cell-free DNA storage and extractions; and biomedical reagents and services. It serves scientific research institutions, high-throughput sequencing service companies, molecular diagnostic reagent manufacturers, pharmaceutical companies, CRO companies, hospitals, and other medical institutions. The company was founded in 2012 and is based in Nanjing, China.